Quantcast

Industry news that matters to you.  Learn more

TGen partner, PBS-Bio, makes first breakthrough drug analysis

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO’s highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).

WaferGen Announces Two Gene Expression Profiling Panels for SmartChip Real-Time PCR System for High Throughput, Cost-Effective Biomarker Discovery and Validation

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced the availability of two gene expression profiling panels for the SmartChip Real-Time PCR System that will enable microRNA and cancer pathway profiling capability.

New Molecular Imaging Biomarker Efficiently Demonstrates Malignant Prostate Tumors

Thomas Jefferson University in Philadelphia, PA and NuView Life Sciences of Park City, UT have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging (MI) compound which identifies genomic expressions linked to prostate cancer (PC).

Quintiles Announces Suite of PI3K Biomarker Assays to Advance Oncology Therapies Targeting this Cancer Pathway

Quintiles today announced a comprehensive suite of biomarker assays to help bio pharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.